Abstract CT030: Genomic and pathologic determinants of response to RP-3500, an ataxia telangiectasia and Rad3-related inhibitor (ATRi), in patients (pts) with DNA damage repair (DDR) loss-of-function (LOF) mutant tumors in the Phase 1/2 TRESR trial
暂无分享,去创建一个
J. Reis-Filho | R. Plummer | S. Lheureux | T. Yap | B. Carneiro | L. Carter | D. Spigel | I. Silverman | E. Rosen | V. Rimkunas | M. Højgaard | P. Manley | D. Ulanet | J. Schonhoft | E. Fontana | Yi Xu | Elizabeth K. Lee | N. Mettu | P. Nejad | M. Koehler | Ezra Rosen | Niharika B. Mettu | Danielle Ulanet